Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.44 USD | -1.88% | -0.10% | +25.63% |
Mar. 12 | HC Wainwright Adjusts IGM Biosciences Price Target to $12 From $7, Maintains Neutral Rating | MT |
Mar. 07 | Earnings Flash (IGMS) IGM BIOSCIENCES Reports Q4 Revenue $651,000 | MT |
Business Summary
Number of employees: 224
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Engineered Immunoglobulin M Antibodies
100.0
%
| 1 | 100.0 % | 2 | 100.0 % | +99.25% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1 | 100.0 % | 2 | 100.0 % | +99.25% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Fred Schwarzer
CEO | Chief Executive Officer | 72 | 03-01-31 |
Misbah Tahir
DFI | Director of Finance/CFO | 49 | 18-12-31 |
T. S. Harigopal
COO | Chief Operating Officer | - | 20-12-31 |
Chris Takimoto
CTO | Chief Tech/Sci/R&D Officer | 65 | 21-07-28 |
Bruce Keyt
CTO | Chief Tech/Sci/R&D Officer | 71 | 09-12-31 |
Lisa Wax
LAW | General Counsel | - | 20-12-31 |
Corporate Officer/Principal | - | 17-12-31 | |
George Gauthier
PRN | Corporate Officer/Principal | 52 | 21-04-11 |
Steven Weber
AUD | Comptroller/Controller/Auditor | 48 | 22-02-28 |
Paul Graffagnino
LAW | General Counsel | - | 20-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Felix Baker
BRD | Director/Board Member | 55 | 21-01-25 |
M. Wilsey
BRD | Director/Board Member | 71 | 19-01-30 |
Fred Schwarzer
CEO | Chief Executive Officer | 72 | 03-01-31 |
Michael Lee
BRD | Director/Board Member | 45 | 19-06-30 |
Julie Hambleton
BRD | Director/Board Member | 66 | 18-08-14 |
Director/Board Member | 55 | 18-07-31 | |
Director/Board Member | 43 | 18-07-31 | |
William Strohl
BRD | Director/Board Member | 71 | 18-07-31 |
Director/Board Member | 49 | 23-10-02 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 25,500,383 | 0 | 0 | 36.48 % |
Stock B | 1 | 33,286,205 | 21,447,677 ( 64.43 %) | 0 |
Company contact information
IGM Biosciences, Inc.
325 East Middlefield Road
94043, Mountain View
+650 965 7873
http://www.igmbio.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.63% | 614M | |
+1.10% | 106B | |
+9.29% | 103B | |
-2.88% | 21.44B | |
-11.89% | 22.11B | |
-26.59% | 20.99B | |
-6.40% | 19.44B | |
-6.58% | 17.6B | |
+5.83% | 13.88B | |
+7.46% | 11.75B |
- Stock
- Equities
- Stock IGM Biosciences, Inc. - Nasdaq
- Company IGM Biosciences, Inc.